A carregar...
Cell-based Immunotherapy Against Gliomas: From Bench to Bedside
Glioblastoma (GBM) comprises 51% of all gliomas and is the most malignant form of brain tumors with a median survival of 18–21 months. Standard-of-care treatment includes maximal surgical resection of the tumor mass in combination with radiation and chemotherapy. However, as the poor survival rate i...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3702108/ https://ncbi.nlm.nih.gov/pubmed/23648695 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2013.80 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|